In the ATHENA study, the cobas® HPV Test (pooled high-risk HPV test with simultaneous individual 16 and 18 genotyping) with reflex cytology detected almost 1.3 times more cases of CIN3 at baseline than cytology with reflex HPV (current standard of care). Learn more below by comparing HPV with genotyping (cobas® HPV Test) and reflex cytology against other screening strategies.
Based on the results from the ATHENA study, the optimal primary screening strategy focuses medical attention on women with HPV 16 and HPV 18 genotypes, and triages other high-risk genotypes, balancing detected cases and intervention.1,5 HPV DNA testing permits confident extension of screening intervals and identifies women who can return to routine screening.6
The cobas® HPV Test:
Learn more about the cobas® HPV Test.
1.Cox JT, Castle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Ob Gyn. 2012:In Press.
2.Wright TC, Stoler MH, Behrens CM, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet & Gynecol. 2012;206:46.e1-11.
3.Data on file, Roche Molecular Systems, Inc.
4.Herzog TJ, Monk BH. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol. 2007;197:566-571.
5.Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection for high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomized controlled trial. Lancet Oncol. 2012; 13:78-88.
6.Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663- 672.